AR043506A1 - PREPARATIONS FOR COMBINATION OF ACETILSALICITY ACID FOR THE PRIMARY PREVENTION OF CARDIOVASCULAR DISORDERS - Google Patents

PREPARATIONS FOR COMBINATION OF ACETILSALICITY ACID FOR THE PRIMARY PREVENTION OF CARDIOVASCULAR DISORDERS

Info

Publication number
AR043506A1
AR043506A1 ARP040100732A ARP040100732A AR043506A1 AR 043506 A1 AR043506 A1 AR 043506A1 AR P040100732 A ARP040100732 A AR P040100732A AR P040100732 A ARP040100732 A AR P040100732A AR 043506 A1 AR043506 A1 AR 043506A1
Authority
AR
Argentina
Prior art keywords
combination
cardiovascular disorders
acid
acetilsalicity
preparations
Prior art date
Application number
ARP040100732A
Other languages
Spanish (es)
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of AR043506A1 publication Critical patent/AR043506A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Combinación que contiene ácido acetilsalicílico (componente A), un inhibidor de la HMG-CoA reductasa (componente B) y, dado el caso, una sustancia antihipertensiva (componente C) para la prevención primaria de trastornos cardiovasculares en pacientes con riesgo alto de sufrir un trastorno cardiovascular, uso de esta combinación y kit que la contiene, a medicamentos que contienen esta combinación y a procedimientos para la preparación de los mismos.Combination containing acetylsalicylic acid (component A), an HMG-CoA reductase inhibitor (component B) and, if necessary, an antihypertensive substance (component C) for the primary prevention of cardiovascular disorders in patients at high risk of suffering a cardiovascular disorder, use of this combination and kit that contains it, to medications that contain this combination and to procedures for preparing them.

ARP040100732A 2003-03-10 2004-03-08 PREPARATIONS FOR COMBINATION OF ACETILSALICITY ACID FOR THE PRIMARY PREVENTION OF CARDIOVASCULAR DISORDERS AR043506A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10310286 2003-03-10
DE10315618 2003-04-04
DE2003151648 DE10351648A1 (en) 2003-03-10 2003-11-05 Synergistic drug combination for primary prevention of cardiovascular disease, especially in high-risk patients, comprising acetylsalicylic acid, HMG-CoA and optionally antihypertensive agent

Publications (1)

Publication Number Publication Date
AR043506A1 true AR043506A1 (en) 2005-08-03

Family

ID=32909553

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040100732A AR043506A1 (en) 2003-03-10 2004-03-08 PREPARATIONS FOR COMBINATION OF ACETILSALICITY ACID FOR THE PRIMARY PREVENTION OF CARDIOVASCULAR DISORDERS

Country Status (5)

Country Link
AR (1) AR043506A1 (en)
CL (1) CL2004000470A1 (en)
DE (1) DE10351648A1 (en)
PE (1) PE20041062A1 (en)
TW (1) TW200505431A (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090023691A1 (en) * 2005-04-07 2009-01-22 Miso Sabovic Delaying the ageing process and disorders caused by ageing
DE102005049293A1 (en) * 2005-10-15 2007-04-26 Bayer Healthcare Ag Combination preparations of salts or o-acetylsalicylic acid

Also Published As

Publication number Publication date
DE10351648A1 (en) 2004-09-23
TW200505431A (en) 2005-02-16
CL2004000470A1 (en) 2005-02-04
PE20041062A1 (en) 2005-02-25

Similar Documents

Publication Publication Date Title
BRPI0617165A2 (en) MEK INHIBITOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND METHODS OF USE THEREOF
AR019507A1 (en) USE OF CYP2D6 INHIBITORS IN COMBINATION THERAPIES
NI201000041A (en) DERIVATIVES AND COMPOSITIONS INCLUDING QUINAZOLINONE 6-, 7-, OR 8 - SUBSTITUTE AND METHODS TO USE THE SAME
BRPI0413363A (en) dosage forms providing controlled release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors
BR0211274A (en) Combination of an aldosterone receptor antagonist and an hmg co-reductase inhibitor
BR122013013162A2 (en) Use of rivastigmine to prepare a transdermal therapeutic system (tts)
NO20073802L (en) Leuprolide acetate and acetylcholine sterase inhibitor or NMDA receptor antagonists for the treatment of Alzheimer's disease
ECSP055525A (en) TYROSINE KINASE INHIBITORS
UY28342A1 (en) NEW COMPOUNDS
GT200900292A (en) "KINASE INHIBITORS P70 S6"
EP1510221A4 (en) Preventives and/or remedies for subjects with the expression or activation of her2 and/or egfr
CL2008002430A1 (en) Benzenesulfonamide derived compounds, cathepsin c inhibitors; pharmaceutical composition comprising them; and its use for the treatment of copd.
BRPI0515319A (en) quinolone analogs
CL2007003557A1 (en) COMPOUNDS DERIVED FROM NITROGEN HETEROCICLES, INHIBITORS OF THE ACTIVITY ON B-RAF; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF CANCER.
BRPI0606506A2 (en) yersinia spp. polypeptides. and methods of use
BRPI0515721A (en) use of a src kinase inhibitor and a bcr-abl inhibitor, pharmaceutical composition and combination
WO2006124684A3 (en) Combination therapy comprising a taxane and a thymidylate synthase inhibitor
BR0213181A (en) Cox-2 inhibitor combinations
DOP2000000022A (en) COMBINATION OF MTP INHIBITORS AND INHIBITORS OF HMG-COA REDUCTASA AND ITS USE IN MEDICINES.
NO20054216L (en) Use of dipyridamole in combination with acetylsalicylic acid and an angiotensin II antagonist for stroke prevention
BR112022026186A2 (en) COMBINATION OF A CBP/P300 BROMODIMANIUM INHIBITOR AND A KRAS INHIBITOR
UY28221A1 (en) PREPARATIONS FOR COMBINATION OF ACETILSALICYL ACID FOR THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASES
AR043506A1 (en) PREPARATIONS FOR COMBINATION OF ACETILSALICITY ACID FOR THE PRIMARY PREVENTION OF CARDIOVASCULAR DISORDERS
AR043327A1 (en) USE OF QUINURENINE 3- HYDROXYLASE INHIBITORS FOR THE TREATMENT OF DIABETES
CL2008000684A1 (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES METFORMIN R - (+) LIPOATE AND A HMG-COA REDUCTASE INHIBITOR; UNIT DOSE FORMULATION; AND USE IN THE TREATMENT OF A DIABETIC COMPLICATION.

Legal Events

Date Code Title Description
FB Suspension of granting procedure
FB Suspension of granting procedure
FA Abandonment or withdrawal